Skip to content

EASL has published several reports on liver disease in Europe and is commissioning work on future publications.

Filter Publications:

Select a year

This policy statement is intended for the general public, affected communities, and policymakers. In parallel, intended for healthcare professionals, an article titled “EASL position paper on the use of COVID-19 vaccines in people with chronic liver diseases, hepatobiliary cancer and liver transplant recipients” was  published, 6 February 2021,  in the Journal of Hepatology. Download the…

Read More

WHO has set a goal of eliminating the hepatitis C virus (HCV) by 2030 but the achievement of this goal is challenged by people who inject drugs (PWID), who account for most of the new cases of HCV infection in high-income countries.

In order to achieve the 2030 WHO viral hepatitis elimination goals, EASL recommends: that all barriers to the uptake of healthcare services by PWID be removed by changing policies and discrimination that hinder access. This includes the decriminalisation of minor, non-violent drug offences and the adoption of an approach based on public health promotion, respect for human rights and evidence.
Full version of Policy Statement

Read More

Create a MyEASL profile to access these resources

With your MyEASL Profile you get access to:

  • Online education through EASL Campus
  • EASL Clinical Practice Guidelines (CPGs)
  • Event specific information through the EASL App
  • Dedicated EASL newsletter
  • And more

Create account

Back To Top